ADHD

Cingulate's CTx-1301, a novel ADHD treatment, gains FDA review, promising rapid relief and sustained efficacy for patients.

New research reveals women with ADHD are diagnosed 5 years later than men, highlighting the need for improved awareness and early intervention.

Discover how Mentavi Health's innovative ADHD assessment enhances diagnosis speed, accuracy, and patient engagement in mental health care.

A recent study reveals higher substance use disorder rates in individuals with ADHD, highlighting significant sex differences and the impact of comorbid psychiatric conditions.

Reproductive psychiatrist Sarah Oreck, MD, MS challenges the FDA's claims linking acetaminophen use in pregnancy to autism and ADHD, advocating for informed maternal care.

Combining cognitive behavioral therapy with medication enhances ADHD treatment in adults, showing significant benefits within 3 months.

Thomas Priolo, MD discusses strategies to manage back-to-school changes in child and adolescent psychiatric care.

Stay updated on key psychopharmacology developments, including new treatments for schizophrenia and breakthroughs in depression therapy.

Our August theme: the complexities of ADHD, including assessment, treatment options, and comorbidities. Share your insights!

Research reveals significant risks of neonatal complications linked to in utero valproic acid exposure, emphasizing the need for careful management during pregnancy.

Cingulate secures a $4.3 million FDA fee waiver for its innovative ADHD treatment, CTx-1301, enhancing patient care with extended efficacy.

Panelists discuss how a patient named Kerstin was diagnosed with attention-deficity/hyperactivity disorder (ADHD) later in life during college when she struggled with organization and scheduling beyond her known dyslexia, leading to successful treatment with various stimulant medications including participation in clinical trials.

Panelists discuss how stimulant and nonstimulant attention-deficity/hyperactivity disorder (ADHD) medications have different adverse effect profiles, with stimulants causing concerns such as misuse potential, cardiovascular effects, tics, and growth suppression.

The FDA has updated ADHD stimulant labels, highlighting weight loss risks in children under 6. Stephen Mateka, DO, shares his updated treatment strategies.

Panelists discuss how a 17-year-old patient’s challenges with inattention, anxiety, and executive dysfunction ahead of college highlight the importance of balancing pharmacologic and nonpharmacologic attention-deficity/hyperactivity disorder (ADHD) treatments. They address concerns about stimulant use and medication diversion.

Panelists discuss how treatment adherence in patients with attention-deficity/hyperactivity disorder (ADHD) is often impacted by forgetfulness and misconceptions and how using tools such as pill organizers can significantly improve consistency and outcomes.

Marc Potenza, PhD, MD, explores the impact of online social activity on ADHD symptoms in adolescents, revealing significant gender differences in brain development and attention.

Panelists discuss how viloxazine fits into both pediatric and adult attention-deficity/hyperactivity disorder (ADHD) treatment plans, especially as a nonstimulant option for patients with complex cases or concerns about stimulant adverse effects, while emphasizing flexible dosing and caregiver involvement.

Panelists discuss how recent clinical studies on viloxazine in children and adolescents with ADHD demonstrated early symptom improvement, dose-dependent efficacy, and tolerability, with the most benefit seen at 400 mg in those aged 11 and under.

The FDA will update ADHD medication labels, warning of weight loss risks in children under 6, urging careful monitoring by health care professionals.

Panelists discuss ADHD nonstimulant medication options with detailed clinical considerations.

Panelists discuss how comprehensive ADHD treatment approaches emphasize combination therapy and immediate implementation.

Panelists discuss the critical role of pediatricians in attention-deficity/hyperactivity disorder (ADHD) diagnosis and treatment challenges.

Panelists discuss how attention-deficity/hyperactivity disorder (ADHD) risk factors include genetic, environmental, and socioeconomic influences.

New research reveals the complex relationship between ADHD and bipolar disorder, highlighting genetic overlaps and treatment considerations for effective management.